The Thesis
PanicFade v4 is a contrarian mean-reversion strategy that bets negative headline shocks are overreacted to and tend to revert toward fundamentals. Entry requires a confluence of signals: a negative sentiment reading (below −0.4), an oversold tape (RSI14 under 35), and price trading below its 20-day moving average — at which point it sizes into the decline. Exits are symmetric and rules-based: it books the reversion when RSI14 climbs back above 50 or price reclaims the SMA20, and it hard-stops positions that keep printing fresh lows on continued negativity, treating that as a genuine fundamental break rather than noise. The design is grounded in recent q-fin work (arXiv:2509.11970, 2025) on asymmetric sentiment overreaction and reversion, and it trades a focused 24-name large-cap universe spanning tech, financials, healthcare, staples, and energy.
Recent Activity
The live sleeve has been notably patient. Most scheduled runs this month executed nothing at all, and as of the Oct 7 run total equity stood at $9,760.56 with $5,238.84 — more than half — parked in cash. The trades that did fire illustrate the playbook cleanly. A WMT position bought at $103.12 in late August was sold at $107.48 three weeks later: a textbook reversion exit. By contrast, BAC bought at $59.86 on Sep 15 was cut at $53.60 on Oct 1 as the name made fresh lows — the hard-stop doing its job — before the strategy re-entered 23 shares at $53.40. That round trip is a useful reminder that fading panic means repeatedly stepping in front of falling names, and not every step is rewarded.
Validation and Backtest
The validation record is the strongest part of the story. Across four walk-forward folds, all four were positive, with returns climbing from 1.6% to 21.7% and the most recent out-of-sample fold posting a 2.44 Sharpe. Headline backtest metrics are solid: 37.93% total return over 1,233 days, a 62.88% win rate, a contained 9.3% max drawdown, and a Probabilistic Sharpe Ratio of 0.985. The full-sample Sharpe is a more modest 0.96, and compounded annual growth works out to just 6.79%.
Strengths and Risks
The strengths are real: robustness across regimes — including a positive fold through the 2022 drawdown year — a shallow drawdown, and a high win rate. But so are the risks. The Deflated Sharpe Ratio is 0.56, only marginally above the 0.5 coin-flip line once 27 trials are accounted for, so the statistical edge is thin after correcting for selection. Turnover is extreme at 5,807%, leaving the strategy highly sensitive to fees and slippage a live book will feel more acutely than a backtest. And recent live performance has been flat-to-slightly-down. PanicFade v4 is a credible, well-validated idea — but a patient, churny one whose margin leaves little room for execution drag.